Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
BACKGROUND: It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment.
OBJECTIVES: To evaluate supplementing dichotomous efficacy with residual disease activity.
METHODS: This post hoc analysis used pooled, patient-level data after tildrakizumab 100 mg (N = 616) or placebo (N = 309) treatment from reSURFACE 1/2 (NCT01722331/NCT01729754) phase 3 clinical trials of patients with moderate to severe plaque psoriasis.
RESULTS: Median baseline Psoriasis Area and Severity Index (PASI) was 17.9 for patients receiving tildrakizumab 100 mg. At Week 12, median PASI was 2.9, whereas dichotomous PASI 90 response rate was 36.9%, and absolute PASI <5.0, <3.0, and <1.0 were 64.0%, 50.8%, and 23.3%, respectively. At Week 28, median PASI was 1.7, whereas PASI 90 response rate was 51.9%, and absolute PASI <5.0, <3.0, and <1.0 were 75.3%, 62.8%, and 38.0%, respectively. Dermatology Life Quality Index and PASI scores were correlated through Week 28 (r = 0.51, p ≤ .0001).
CONCLUSIONS: Disease activity was more reliably estimated by PASI scores than percentage PASI improvement; this may partially explain efficacy disparities between clinical trials and practice. These results suggest supplementing dichotomous PASI improvement with PASI scores and consideration of patient treatment goals could facilitate clinical decisions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
The Journal of dermatological treatment - 33(2022), 1 vom: 02. Feb., Seite 219-228 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gordon, K B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 15.02.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09546634.2020.1747590 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309333911 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309333911 | ||
| 003 | DE-627 | ||
| 005 | 20231225133701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09546634.2020.1747590 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309333911 | ||
| 035 | |a (NLM)32349565 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gordon, K B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment | ||
| 520 | |a OBJECTIVES: To evaluate supplementing dichotomous efficacy with residual disease activity | ||
| 520 | |a METHODS: This post hoc analysis used pooled, patient-level data after tildrakizumab 100 mg (N = 616) or placebo (N = 309) treatment from reSURFACE 1/2 (NCT01722331/NCT01729754) phase 3 clinical trials of patients with moderate to severe plaque psoriasis | ||
| 520 | |a RESULTS: Median baseline Psoriasis Area and Severity Index (PASI) was 17.9 for patients receiving tildrakizumab 100 mg. At Week 12, median PASI was 2.9, whereas dichotomous PASI 90 response rate was 36.9%, and absolute PASI <5.0, <3.0, and <1.0 were 64.0%, 50.8%, and 23.3%, respectively. At Week 28, median PASI was 1.7, whereas PASI 90 response rate was 51.9%, and absolute PASI <5.0, <3.0, and <1.0 were 75.3%, 62.8%, and 38.0%, respectively. Dermatology Life Quality Index and PASI scores were correlated through Week 28 (r = 0.51, p ≤ .0001) | ||
| 520 | |a CONCLUSIONS: Disease activity was more reliably estimated by PASI scores than percentage PASI improvement; this may partially explain efficacy disparities between clinical trials and practice. These results suggest supplementing dichotomous PASI improvement with PASI scores and consideration of patient treatment goals could facilitate clinical decisions | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Psoriasis Area and Severity Index (PASI) | |
| 650 | 4 | |a disease activity | |
| 650 | 4 | |a tildrakizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tildrakizumab |2 NLM | |
| 650 | 7 | |a DEW6X41BEK |2 NLM | |
| 700 | 1 | |a Reich, K |e verfasserin |4 aut | |
| 700 | 1 | |a Crowley, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Korman, N J |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, F T |e verfasserin |4 aut | |
| 700 | 1 | |a Poulin, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Spelman, L |e verfasserin |4 aut | |
| 700 | 1 | |a Yamauchi, P S |e verfasserin |4 aut | |
| 700 | 1 | |a Mendelsohn, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Parno, J |e verfasserin |4 aut | |
| 700 | 1 | |a Rozzo, S J |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, C N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of dermatological treatment |d 1992 |g 33(2022), 1 vom: 02. Feb., Seite 219-228 |w (DE-627)NLM088851680 |x 1471-1753 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:1 |g day:02 |g month:02 |g pages:219-228 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09546634.2020.1747590 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 1 |b 02 |c 02 |h 219-228 | ||